Chem Shift validation: AVS_full
BMRB Entry DOI: doi:10.13018/BMR53033
NMR-STAR file interactive viewer.
NMR-STAR v3 text file.
All files associated with the entry
Citation: Petrovic, Ivana; Tatli, Meltem; Desai, Samit; Grahl, Anne; Ni, Dongchun; Stahlberg, Henning; Spang, Anne; Grzesiek, Stephan; Abiko, Layara. "Arrestin recognizes GPCRs independently of the receptor state" Proc. Natl. Acad. Sci. U.S.A. 122, e2501487122-e2501487122 (2025).
PubMed: 40372433
Assembly members:
entity_1, polymer, 315 residues, Formula weight is not available
entity_2, polymer, 393 residues, Formula weight is not available
entity_3, polymer, 29 residues, Formula weight is not available
entity_CVD, non-polymer, 406.474 Da.
Natural source: Common Name: turkey Taxonomy ID: 9103 Superkingdom: Eukaryota Kingdom: Metazoa Genus/species: Meleagris gallopavo
Experimental source: Production method: recombinant technology Host organism: Spodoptera frugiperda Vector: pFastBac1
Entity Sequences (FASTA):
entity_1: MGAELLSQQWEAGMSLLMAL
VVLLIVAGNVLVIAAIGSTQ
RLQTLTNLFITSLACADLVV
GLLVVPFGATLVVRGTWLWG
SFLCELWTSLDVLCVTASVE
TLCVIAIDRYLAITSPFRYQ
SLMTRARAKVIICTVWAISA
LVSFLPIMMHWWRDEDPQAL
KCYQDPGCCCFVTNRAYAIA
SSIISFYIPLLIMIFVALRV
YREAKEQIRKIDRASKRKTS
RVMLMREHKALKTLGIIMGV
FTLCWLPFFLVNIVNVFNRD
LVPKWLFVAFNWLGYANSAM
NPIILCRSPDFRKAFKRLLA
FPRKADRRLHHHHHH
entity_2: MGDKGTRVFKKASPNGKLTV
YLGKRDFVDHIDLVDPVDGV
VLVDPEYLKERRVYVTLTCA
FRYGREDLDVLGLTFRKDLF
VANVQSFPPAPEDKKPLTRL
QERLIKKLGEHAYPFTFEIP
PNLPCSVTLQPGPEDTGKAC
GVDYEVKAFLAENLEEKIHK
RNSVRLVIRKVQYAPERPGP
QPTAETTRQFLMSDKPLHLE
ASLDKEIYYHGEPISVNVHV
TNNTNKTVKKIKISVRQYAD
IVLFNTAQYKVPVAMEEADD
TVAPSSTFSKVYTLTPFLAN
NREKRGLALDGKLKHEDTNL
ASSTLLREGANREILGIIVS
YKVKVKLVVSRGGLLGDLAS
SDVAVELPFTLMHPKPKEEP
PHREVPENETPVDTNLIELD
TNDDDIVFEDFAR
entity_3: ARGRTPPSLGPQDESCTTAS
SSLAKDTSS
| Data type | Count |
| 15N chemical shifts | 13 |
| 1H chemical shifts | 13 |
| Entity Assembly ID | Entity Name | Entity ID |
|---|---|---|
| 1 | TS-b1-adrenergic receptor in complex with isoprenaline, conformer 1 | 1 |
| 2 | arrestin2 | 2 |
| 3 | V2Rpp | 3 |
| 4 | carvedilol | 4 |
Entity 1, TS-b1-adrenergic receptor in complex with isoprenaline, conformer 1 315 residues - Formula weight is not available
| 1 | MET | GLY | ALA | GLU | LEU | LEU | SER | GLN | GLN | TRP | ||||
| 2 | GLU | ALA | GLY | MET | SER | LEU | LEU | MET | ALA | LEU | ||||
| 3 | VAL | VAL | LEU | LEU | ILE | VAL | ALA | GLY | ASN | VAL | ||||
| 4 | LEU | VAL | ILE | ALA | ALA | ILE | GLY | SER | THR | GLN | ||||
| 5 | ARG | LEU | GLN | THR | LEU | THR | ASN | LEU | PHE | ILE | ||||
| 6 | THR | SER | LEU | ALA | CYS | ALA | ASP | LEU | VAL | VAL | ||||
| 7 | GLY | LEU | LEU | VAL | VAL | PRO | PHE | GLY | ALA | THR | ||||
| 8 | LEU | VAL | VAL | ARG | GLY | THR | TRP | LEU | TRP | GLY | ||||
| 9 | SER | PHE | LEU | CYS | GLU | LEU | TRP | THR | SER | LEU | ||||
| 10 | ASP | VAL | LEU | CYS | VAL | THR | ALA | SER | VAL | GLU | ||||
| 11 | THR | LEU | CYS | VAL | ILE | ALA | ILE | ASP | ARG | TYR | ||||
| 12 | LEU | ALA | ILE | THR | SER | PRO | PHE | ARG | TYR | GLN | ||||
| 13 | SER | LEU | MET | THR | ARG | ALA | ARG | ALA | LYS | VAL | ||||
| 14 | ILE | ILE | CYS | THR | VAL | TRP | ALA | ILE | SER | ALA | ||||
| 15 | LEU | VAL | SER | PHE | LEU | PRO | ILE | MET | MET | HIS | ||||
| 16 | TRP | TRP | ARG | ASP | GLU | ASP | PRO | GLN | ALA | LEU | ||||
| 17 | LYS | CYS | TYR | GLN | ASP | PRO | GLY | CYS | CYS | CYS | ||||
| 18 | PHE | VAL | THR | ASN | ARG | ALA | TYR | ALA | ILE | ALA | ||||
| 19 | SER | SER | ILE | ILE | SER | PHE | TYR | ILE | PRO | LEU | ||||
| 20 | LEU | ILE | MET | ILE | PHE | VAL | ALA | LEU | ARG | VAL | ||||
| 21 | TYR | ARG | GLU | ALA | LYS | GLU | GLN | ILE | ARG | LYS | ||||
| 22 | ILE | ASP | ARG | ALA | SER | LYS | ARG | LYS | THR | SER | ||||
| 23 | ARG | VAL | MET | LEU | MET | ARG | GLU | HIS | LYS | ALA | ||||
| 24 | LEU | LYS | THR | LEU | GLY | ILE | ILE | MET | GLY | VAL | ||||
| 25 | PHE | THR | LEU | CYS | TRP | LEU | PRO | PHE | PHE | LEU | ||||
| 26 | VAL | ASN | ILE | VAL | ASN | VAL | PHE | ASN | ARG | ASP | ||||
| 27 | LEU | VAL | PRO | LYS | TRP | LEU | PHE | VAL | ALA | PHE | ||||
| 28 | ASN | TRP | LEU | GLY | TYR | ALA | ASN | SER | ALA | MET | ||||
| 29 | ASN | PRO | ILE | ILE | LEU | CYS | ARG | SER | PRO | ASP | ||||
| 30 | PHE | ARG | LYS | ALA | PHE | LYS | ARG | LEU | LEU | ALA | ||||
| 31 | PHE | PRO | ARG | LYS | ALA | ASP | ARG | ARG | LEU | HIS | ||||
| 32 | HIS | HIS | HIS | HIS | HIS |
Entity 2, arrestin2 393 residues - Formula weight is not available
The construct includes residues 1-393 of Arrestin2.
| 1 | MET | GLY | ASP | LYS | GLY | THR | ARG | VAL | PHE | LYS | ||||
| 2 | LYS | ALA | SER | PRO | ASN | GLY | LYS | LEU | THR | VAL | ||||
| 3 | TYR | LEU | GLY | LYS | ARG | ASP | PHE | VAL | ASP | HIS | ||||
| 4 | ILE | ASP | LEU | VAL | ASP | PRO | VAL | ASP | GLY | VAL | ||||
| 5 | VAL | LEU | VAL | ASP | PRO | GLU | TYR | LEU | LYS | GLU | ||||
| 6 | ARG | ARG | VAL | TYR | VAL | THR | LEU | THR | CYS | ALA | ||||
| 7 | PHE | ARG | TYR | GLY | ARG | GLU | ASP | LEU | ASP | VAL | ||||
| 8 | LEU | GLY | LEU | THR | PHE | ARG | LYS | ASP | LEU | PHE | ||||
| 9 | VAL | ALA | ASN | VAL | GLN | SER | PHE | PRO | PRO | ALA | ||||
| 10 | PRO | GLU | ASP | LYS | LYS | PRO | LEU | THR | ARG | LEU | ||||
| 11 | GLN | GLU | ARG | LEU | ILE | LYS | LYS | LEU | GLY | GLU | ||||
| 12 | HIS | ALA | TYR | PRO | PHE | THR | PHE | GLU | ILE | PRO | ||||
| 13 | PRO | ASN | LEU | PRO | CYS | SER | VAL | THR | LEU | GLN | ||||
| 14 | PRO | GLY | PRO | GLU | ASP | THR | GLY | LYS | ALA | CYS | ||||
| 15 | GLY | VAL | ASP | TYR | GLU | VAL | LYS | ALA | PHE | LEU | ||||
| 16 | ALA | GLU | ASN | LEU | GLU | GLU | LYS | ILE | HIS | LYS | ||||
| 17 | ARG | ASN | SER | VAL | ARG | LEU | VAL | ILE | ARG | LYS | ||||
| 18 | VAL | GLN | TYR | ALA | PRO | GLU | ARG | PRO | GLY | PRO | ||||
| 19 | GLN | PRO | THR | ALA | GLU | THR | THR | ARG | GLN | PHE | ||||
| 20 | LEU | MET | SER | ASP | LYS | PRO | LEU | HIS | LEU | GLU | ||||
| 21 | ALA | SER | LEU | ASP | LYS | GLU | ILE | TYR | TYR | HIS | ||||
| 22 | GLY | GLU | PRO | ILE | SER | VAL | ASN | VAL | HIS | VAL | ||||
| 23 | THR | ASN | ASN | THR | ASN | LYS | THR | VAL | LYS | LYS | ||||
| 24 | ILE | LYS | ILE | SER | VAL | ARG | GLN | TYR | ALA | ASP | ||||
| 25 | ILE | VAL | LEU | PHE | ASN | THR | ALA | GLN | TYR | LYS | ||||
| 26 | VAL | PRO | VAL | ALA | MET | GLU | GLU | ALA | ASP | ASP | ||||
| 27 | THR | VAL | ALA | PRO | SER | SER | THR | PHE | SER | LYS | ||||
| 28 | VAL | TYR | THR | LEU | THR | PRO | PHE | LEU | ALA | ASN | ||||
| 29 | ASN | ARG | GLU | LYS | ARG | GLY | LEU | ALA | LEU | ASP | ||||
| 30 | GLY | LYS | LEU | LYS | HIS | GLU | ASP | THR | ASN | LEU | ||||
| 31 | ALA | SER | SER | THR | LEU | LEU | ARG | GLU | GLY | ALA | ||||
| 32 | ASN | ARG | GLU | ILE | LEU | GLY | ILE | ILE | VAL | SER | ||||
| 33 | TYR | LYS | VAL | LYS | VAL | LYS | LEU | VAL | VAL | SER | ||||
| 34 | ARG | GLY | GLY | LEU | LEU | GLY | ASP | LEU | ALA | SER | ||||
| 35 | SER | ASP | VAL | ALA | VAL | GLU | LEU | PRO | PHE | THR | ||||
| 36 | LEU | MET | HIS | PRO | LYS | PRO | LYS | GLU | GLU | PRO | ||||
| 37 | PRO | HIS | ARG | GLU | VAL | PRO | GLU | ASN | GLU | THR | ||||
| 38 | PRO | VAL | ASP | THR | ASN | LEU | ILE | GLU | LEU | ASP | ||||
| 39 | THR | ASN | ASP | ASP | ASP | ILE | VAL | PHE | GLU | ASP | ||||
| 40 | PHE | ALA | ARG |
Entity 3, V2Rpp 29 residues - Formula weight is not available
This synthetic peptide corresponds to the C-terminal 29 residues of the vasopressin receptor 2 and contains eight phosphorylation sites.
| 1 | ALA | ARG | GLY | ARG | THR | PRO | PRO | SER | LEU | GLY | ||||
| 2 | PRO | GLN | ASP | GLU | SER | CYS | THR | THR | ALA | SER | ||||
| 3 | SER | SER | LEU | ALA | LYS | ASP | THR | SER | SER |
Entity 4, carvedilol - C24 H26 N2 O4 - 406.474 Da.
| 1 | CVD |
sample_1: Turkey B1AR, [U-15N]-Val, 200 uM; carvedilol 2 mM; TRIS 20 mM; sodium chloride 100 mM; n-Decyl-b-D-maltoside 65 mM; ascorbate 20 mM; sodium azide 0.02%; D2O 5%; arrestin2 240 uM; V2Rpp 800 uM
sample_conditions_1: pH: 7.5; pressure: 1 atm; temperature: 304 K
| Name | Sample | Sample state | Sample conditions |
|---|---|---|---|
| 2D 1H-15N TROSY | sample_1 | isotropic | sample_conditions_1 |
NMRDraw v11.4 - chemical shift assignment, peak picking
CcpNMR v2.4.2 - data analysis
Download HSQC peak lists in one of the following formats:
CSV: Backbone
or all simulated peaks
SPARKY: Backbone
or all simulated peaks